GRHPR Inhibitors
GRHPR, or glyoxylate reductase/hydroxypyruvate reductase, is an enzyme primarily found in the liver and kidneys, playing a crucial role in the metabolism of glyoxylate and hydroxypyruvate. The function of GRHPR is essential for maintaining normal physiological levels of these metabolites, as dysregulation can lead to the accumulation of oxalate and subsequent formation of kidney stones or contribute to the development of primary hyperoxaluria type 2 (PH2). GRHPR catalyzes the reduction of glyoxylate to glycolate and hydroxypyruvate to D-glycerate, utilizing NADH as a cofactor in both reactions. Through these enzymatic activities, GRHPR helps to divert glyoxylate and hydroxypyruvate away from pathways leading to oxalate synthesis, thus preventing the accumulation of oxalate and maintaining metabolic homeostasis.
Inhibiting GRHPR activity represents a strategy for reducing oxalate production and mitigating the complications associated with oxalate-related diseases such as kidney stones and PH2. General mechanisms of inhibition may involve targeting the active site of GRHPR to disrupt its catalytic activity, preventing the conversion of glyoxylate and hydroxypyruvate to their respective reduced forms. Additionally, modulating the expression or stability of GRHPR through strategies such as gene silencing or protein degradation pathways could further inhibit its enzymatic activity and reduce oxalate production. Understanding the precise mechanisms of GRHPR inhibition and its impact on oxalate metabolism will provide valuable insights into interventions for oxalate-related diseases.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is a polysulfonated naphthylurea that inhibits various enzymes, including the purine metabolism enzyme GRHPR. It can inhibit GRHPR activity by binding to the active site of the enzyme, preventing substrate binding and hence reducing its functional activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Though not directly targeting GRHPR, it can inhibit RTKs involved in pathways that affect GRHPR's functional activity. By inhibiting these RTKs, downstream signaling events that regulate GRHPR activity could be impacted, leading to decreased GRHPR function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, Rapamycin can decrease protein synthesis and cellular proliferation. This may influence the functional activity of GRHPR, as the protein's activity is often linked to cellular proliferation and metabolic activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can potentially inhibit the PI3K-Akt pathway, a pathway known to regulate various cellular functions, potentially including the functional activity of GRHPR. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002. By inhibiting PI3K, Wortmannin can potentially decrease the functional activity of GRHPR by inhibiting downstream signaling in the PI3K-Akt pathway. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor. By inhibiting EGFR, downstream signaling events that might regulate GRHPR activity could be affected, leading to decreased activity of GRHPR. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor. By inhibiting BCR-ABL, Imatinib could potentially decrease the functional activity of GRHPR, if GRHPR's activity is influenced by BCR-ABL or its downstream signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor. By inhibiting EGFR, Gefitinib could potentially decrease the functional activity of GRHPR, if EGFR or its downstream signaling pathways play a role in regulating GRHPR activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, including BCR-ABL. By inhibiting these kinases, Dasatinib could potentially inhibit the functional activity of GRHPR, if these kinases or their downstream signaling pathways influence GRHPR activity. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib is an EGFR family inhibitor. It can inhibit the EGFR family, potentially influencing downstream signaling events that could regulate GRHPR activity, leading to decreased GRHPR activity. | ||||||